Gilead Sciences' revenue may be shrinking, but CEO John Milligan just got an 11% raise

27th March 2018 Uncategorised 0

Declining sales in Gilead’s hepatitis C franchise drove the company’s total revenues for 2017 down 14% to $26.1 billion. But that didn’t stop Gilead’s board from boosting CEO John Milligan’s pay package to $15.4 million.

More: Gilead Sciences' revenue may be shrinking, but CEO John Milligan just got an 11% raise
Source: fierce